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ABSTRACT
Every year more than 8 million people suffer from cancer-related deaths worldwide 
[1]. Metastasis, the spread of cancer to distant sites, accounts for 90% of these 
deaths. A promising target for blocking tumor progression, without causing severe 
side effects [2], is Tumor Endothelial Marker 8 (TEM8), an integrin-like cell surface 
protein expressed predominantly in the tumor endothelium and in cancer cells [3, 4]. 
Here, we have investigated the role of TEM8 in cancer progression, angiogenesis and 
metastasis in invasive breast cancer, and validated the main findings and important 
results in colorectal cancer. We show that the loss of TEM8 in cancer cells results 
in inhibition of cancer progression, reduction in tumor angiogenesis and reduced 
metastatic burden in breast cancer mouse models. Furthermore, we show that TEM8 
regulates cancer progression by affecting the expression levels of cell cycle-related 
genes. Taken together, our findings may have broad clinical and therapeutic potential 
for breast and colorectal primary tumor and metastasis treatment by targeting TEM8.
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INTRODUCTION
Breast cancer is the fifth leading cause of cancer 
death, and colorectal cancer (CRC) is the fourth leading 
cause of cancer death, worldwide [1]. Breast cancer is the 
most frequently diagnosed cancer in women, while CRC 
is the second and third most frequently diagnosed cancer 
in women and men, respectively [1]. Despite continuous 
advances in prevention, detection and therapy of breast 
cancer; 5% of patients have metastases at the time of 
diagnosis and 30% of patients develop metastases during 
treatment [5]. In CRC, between 15–25% of CRC patients 
present with metastasis at the time of diagnosis [6]. 
Metastatic cancer is nearly incurable, and the use of end-
stage chemotherapy, which is often the standard of care, 
may be even worse for patients compared to no treatment 
[7]. Therefore, there is a chronic need for new treatments 
to prevent and to cure metastatic cancer. Targeting specific 
components of the metastatic cascade might offer new 
hopes for therapeutic strategies [8].
Tumor Endothelial Marker 8 (TEM8), also 
known as Anthrax Receptor 1 (ANTXR1), is highly up-
regulated in the tumor endothelium and is expressed in 
many cancer types, including breast cancer and CRC 
[4]. The physiological function of TEM8 is not yet fully 
understood, although it has been found to be a functional 
anthrax toxin receptor [9]. Initial studies of TEM8 knock 
out (KO) mice found TEM8 to be dispensable in a normal 
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physiological state [10]. However, in a cancer setting 
TEM8 has been shown to be required for optimal tumor 
growth and angiogenesis (the formation of new blood 
vessels) [2]. TEM8 has been shown to bind collagen I 
and the C5 domain of collagen α3(VI), which are both 
pro-angiogenic extracellular matrix (ECM) components 
[11, 12]. The role of TEM8 in angiogenesis was further 
elucidated when it was shown that TEM8 interacts with 
vascular endothelial growth factor receptor 2 (VEGFR2) 
and thus modulates downstream VEGF signaling [13, 14]. 
Primary tumor growth and metastasis are highly dependent 
on angiogenesis, since tumors can only grow to a size of 
a few millimeters without forming new blood vessels to 
supply the expanding tumor with oxygen and nutrients [15]. 
Tumor angiogenesis is hypothesized to be an important 
factor for the escape and spread of metastatic cells due to 
the formation of leaky blood vessels, therefore, treatments 
that target TEM8 could potentially distinguish between 
physiological and pathological angiogenesis and inhibit 
cancer progression without causing severe side effects. 
 More recently, a second TEM8 KO mouse was 
generated and TEM8 was characterized as an essential 
component in controlling endothelial and fibroblast 
homeostasis in the skin [16]. The skin of TEM8 KO mice 
presented with altered levels of endothelial basement 
membrane components including members of collagen 
type I and VI, as well as hyperproliferative and leaky blood 
vessels [16]. These findings contradict previous findings 
showing no role for TEM8 in a normal physiological state. 
In osteosarcoma cells the knock-down of TEM8 led to 
reduced cell proliferation [17], showing that TEM8 can 
have dual roles depending on the setting. Furthermore, 
TEM8 was found to interact with lipoprotein receptor-
related protein 6 (LRP6); modulating signaling down-
stream of Wnt, a protein that induces both cell proliferation 
and migration [18, 19]. TEM8 was shown to be a 
functional marker for cancer stem cells in breast cancer, 
by activating Wnt signaling and by acting in a signaling 
network with collagen VI, impacting breast cancer stem 
cell characteristics and metastatic potential by positively 
regulating tumor growth [20]. TEM8 was associated with 
a more invasive and aggressive phenotype in breast cancer 
[20] and was found to be upregulated in invasive breast 
cancer [3]. Furthermore, we found that TEM8 expression is 
higher in tumors compared to normal tissue in both breast 
cancer and colon cancer patient samples. 
We used CRISPR/Cas9 to create TEM8 KO cells 
and found that tumor progression in vivo is significantly 
inhibited when cancer cell TEM8 expression is lost. Using 
microarrays, we demonstrate the altered expression pattern 
of many genes in cancer cells upon TEM8 KO, the majority 
of which are genes involved in cell cycle regulation. 
Importantly, we show that tumor angiogenesis is reduced 
and the metastatic burden is significantly lowered in breast 
cancer when TEM8 is disrupted in cancer cells. These data 
highlight the role of cancer cell-derived TEM8 in driving 
cancer progression and further demonstrate its potential as 
a therapeutic target to fight the disease. 
RESULTS
Expression of TEM8 is associated with disease in 
breast and colorectal cancer
TEM8 has previously been suggested to be 
specifically expressed in the tumor microenvironment [21]. 
We therefore explored the expression levels of TEM8 and 
its possible association with the disease phenotype in breast 
cancer and colorectal cancer. We used Disease-Specific 
Genomic Analysis (DSGA) [22], a computational data 
analysis method that mathematically identifies the signature 
of healthy cells from either one cell type or tissue, the 
normal component (NcT). DSGA then highlights aberrant 
expression signatures of diseased cells or tissue, the Disease 
component (DcT), by comparing it to the healthy signature. 
To perform the DSGA-decomposition [22] we 
combined gene expression microarray data from a breast 
cancer cohort at the Dutch Cancer Institute (NKI) of 295 
breast cancer tumors [23] and 13 normal breast tissue 
samples (BCN) (comprising 10 pathologically normal 
breast samples distant to tumors in breast cancer patients 
and 3 reduction mammoplasties [22]). We found the 
expression of TEM8 in the normal-like cell states of tumors, 
NcT, to be significantly higher than in cell states of normal 
breast tissue (Figure 1A). This difference was independent 
of the breast cancer molecular subtype. No difference in 
the distributions of aberrant cell state (DcT) compared to 
normal tissue was observed (data not shown). These results 
are in agreement with previous reports [2, 3, 20]. While 
the overall distribution of TEM8 was similar to normal 
in the disease component of tumors, patients with her2-
overexpressing tumors that contained high levels of TEM8 
presented with a significantly worse association with overall 
survival (Figure 1B) and metastasis (Figure 1C).
Next, we analyzed the normal component and disease 
component of a publicly available colorectal cancer data 
set consisting of 13 normal tissue samples (7 samples 
from normal colonic crypts (NC) and 6 samples from 
normal colonic surface epithelium (NS)), 17 adenomas, 
17 carcinomas and 11 metastases [24]. We performed 
3 independent DSGA data decompositions: using the 
combined normal samples, using only the normal colonic 
crypt samples, and using only the normal colonic surface 
epithelium samples. The results were similar, showing 
the behavior of TEM8 to be the same, whether tumors 
originate from crypt cells, surface cells, or a combination of 
the two. We found that more aggressive tumors had higher 
TEM8 in the normal component compared to normal and 
adenomas (Figure 1D). As with the breast cancer data there 
was no significant difference in the disease component 
in the CRC data set. Unfortunately, no survival data was 
available to further explore the association of TEM8 levels 
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in the disease component. Overall, these data demonstrate 
that TEM8 expression is increased in both breast and CRC 
tumors compared to healthy tissue, and that high levels 
of TEM8 are associated with worse outcome in terms of 
patient survival and metastasis.
TEM8 reduces the expression levels of cell cycle-
related genes
The effect of TEM8 on cancer cell growth has 
previously been assessed by growing human tumor 
xenografts in a TEM8 KO mouse model [2]. Host-derived 
TEM8 was found to positively influence the growth of 
primary tumors, however tumor growth was still observed 
in the TEM8 KO mouse suggesting that tumor-derived 
TEM8 could also promote growth. 
To assess this and to investigate if there are molecular 
changes caused by the loss of TEM8, we created TEM8 
KO clones of the human metastatic breast cancer cell 
line MDA-MB-231 (MDA) and the human metastatic 
colorectal cancer cell line SW620 using the CRISPR/Cas9 
gene-editing technique. Clones from each cell line with no 
detectable TEM8 mRNA were chosen for further analysis 
(Figure 2A, 2B). The selected cell lines, termed MDA 
TEM8 KO and SW620 TEM8 KO, were Sanger sequenced 
and examined for indels and the indels were found to be 
homozygous (Supplementary Figure 1). The MDA TEM8 
KO cell line had an insertion and the SW620 cell line had 
a deletion leading to premature stop codons in exon 1 
(Supplementary Figure 1).  
Using the generated TEM8 KO cell lines, we carried 
out a microarray to compare gene expression in TEM8 KO 
cell lines with their respective controls (Supplementary 
Table 1). We performed a network analysis, where the gene 
names from the microarray were mapped onto a human 
interactome (see Materials and Methods), to assess whether 
TEM8 regulates the expression levels of potential interaction 
partners and their wider interaction networks. The analysis 
revealed no overall trend in the changed mRNA expression 
in response to a TEM8 KO, particularly when comparing 
between the two cancer types, but showed that the TEM8 
KO affected many of the genes interacting with the TEM8 
interaction partners (Supplementary Figure 2). 
Next, we performed gene clustering analysis on 
the gene expression data to determine if there are any 
groups of genes that are affected by the loss of TEM8 in 
Figure 1: Expression of TEM8 is associated with disease in breast and colorectal cancer. (A) DSGA-transformation of the 
NKI breast cancer (BC) data set, as described in Materials and Methods. Expression of TEM8 in the “normal-like” cell states of tumors 
(NcT) from basal (n = 49), her2 positive (n = 53), and luminal breast cancers (n = 193) are significantly higher than in normal breast 
tissue (n = 13). (B–C) Kaplan–Meyer survival curves, death (p = 0.0124) and metastasis (p = 0.0243), of breast cancer patients with her2-
overexpressing breast tumors based on TEM8 expression. Group 1 is the bottom 33% and Group 2 is the top 33% of TEM8 expression 
in the disease component (DcT). (D) DSGA-transformation of the CRC data set. Expression of TEM8 in the “normal-like” cell states of 
tumors (NcT) from adenoma (n = 17), carcinoma (n = 17), and metastasis (n = 11) are significantly higher compared to normal (normal 
crypt and surface epithelium combined, n = 13) samples.  
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common to both breast and CRC cells (Figure 2C). Two 
clusters contained genes that were up-regulated in both 
MDA and SW620 TEM8 KO cell lines, and an additional 
cluster which contained genes that were down-regulated 
(Figure 2C). We performed functional gene ontological 
analysis of the gene clusters (Supplementary Table 2), and 
found that the two up-regulated clusters contained genes 
involved in cell cycle regulation and kinetochore assembly, 
whereas the down-regulated cluster contained genes 
involved in RNA processing (Figure 2C). 
As an example we performed an interaction network 
analysis of the cell cycle-related cluster, which showed 
several cancer-related pathways affected by the loss of 
TEM8 such as members of the MAP kinase pathway 
(Figure 2D), which have previously been shown to be 
modulated by TEM8 in osteosarcoma cells [17]. The 
Figure 2: The expression of cell cycle-related genes is enriched in TEM8 KO cancer cells. (A and B) Real-time quantitative 
PCR evaluating the mRNA expression levels of TEM8 confirms knockdown in MDA TEM8 KO and SW620 TEM8 KO cell lines compared 
to their control (ctrl) cell lines, MDA and SW620 respectively. n = 3 independent experiments, Statistical significance was assessed by 
One-way ANOVA, p < 0.0001. (C) Clustering analysis of gene expression in MDA and SW620 TEM8 KO cell lines (n = 3 independent 
experiments). The average of values for probes corresponding to one gene was used in the comparison. Proteins involved in blocking cell 
cycle and division are highlighted. (D) Network analysis of proteins interacting in the cell cycle cluster where similar in both MDA and 
SW620 cell lines. Node color here depicts values from SW620 control and SW620 TEM8 KO cell lines.
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tumor suppressor p53 (USP42) [25] was also enriched 
in TEM8 KO cells (Figure 2D). In addition, the GTPase 
BCR that activates Cdc42 and Rac1, both proteins involved 
in migration and invasion of cells [26], is enriched in 
TEM8 KO cells. Similarly, we observed an enrichment of 
SMARCE1 and SMARCB1 (Figure 2D), two proteins that 
are core components of the BAF (SWI/SNF) chromatin 
remodeling complex and have been implicated as inhibitors 
of tumor formation [27]. Interestingly, SMARCB1 was 
previously found to be among the top candidate genes in a 
genetic screen for TEM8 interaction partners [28].  Taken 
together, these data suggest that the loss of TEM8 alters 
the gene expression profiles of MDA and SW620 cells, 
with common changes occurring in cell cycle-related genes 
known to be important for cancer progression. 
TEM8 affects in vivo tumor growth
Next, we investigated the importance of TEM8 in 
cancer proliferation since the expression of cell cycle-
regulated genes was found to be increased upon loss of 
TEM8. We first compared proliferation of the TEM8 KO 
cells with control cells in both 2D and 3D proliferation 
assays. In the 2D proliferation assay, the MDA TEM8 
KO cells proliferated significantly more slowly than 
MDA control cells (Supplementary Figure 3A). In a 3D 
proliferation assay MDA TEM8 KO cells showed a not 
significant trend of slowed proliferation compared to MDA 
control cells (Supplementary Figure 3B). Conversely, 
the control and TEM8 KO SW620 cells showed no 
difference in either 2D or 3D proliferation (Supplementary 
Figure 3C–3D). Hence, KO of TEM8 affects proliferation 
of breast cancer cells, but not colon cancer cells, in vitro.
To study the importance of TEM8 in cancer 
proliferation in vivo we used an orthotopic breast cancer 
model where either MDA control or MDA TEM8 KO 
cells were injected into the fat pad of mice. Tumor growth 
was dramatically reduced when TEM8 was knocked out 
compared to control (Figure 3A). At the experimental 
endpoint (160 days), 33% of the mice injected with MDA 
TEM8 KO cells were tumor-free. In the remaining 66% 
of the mice injected with MDA TEM8 KO cells, tumor 
growth was significantly slowed compared to controls 
which all developed tumors (Figure 3A). Consequently, 
the median survival rate was prolonged to 100 days, 
more than 4 times longer than the control group (24 days, 
Figure 3B, p < 0.0001). These results are consistent with 
the in vitro proliferation data, and suggest that TEM8 
plays a role in breast cancer proliferation in vivo.
To validate our findings in a second in vivo cancer 
model, we tested the effects of TEM8 KO on subcutaneous 
tumor growth of the SW620 cells. Similar to the breast 
cancer model, tumor growth was significantly inhibited 
when TEM8 was knocked out (Figure 3C). In particular, 
when SW620 TEM8 KO tumors reached a size of around 
200 mm2, their further growth was stalled. The median 
survival for the SW620 control mice was 27.5 days while 
in contrast, the SW620 TEM8 KO group had a median 
survival of 107.5 days (4 times longer than the control 
group, Figure 3D, p = 0.0108). These results demonstrate 
a significantly prolonged survival for the mice bearing 
SW620 TEM8 KO tumors and indicate that TEM8 is 
important for CRC tumor growth in vivo. Interestingly, 
the differences between the CRC in vitro and in vivo data 
suggest that the effect of TEM8 depends on the surrounding 
microenvironment.   
To confirm that the tumors did not express TEM8 in 
vivo at the experimental end points, tumor sections were 
stained for TEM8 by immunohistochemistry (IHC). TEM8 
was only expressed in control and not in TEM8 KO tumors 
(Figure 3E). Furthermore, both breast and CRC tumors were 
assessed by IHC for cells undergoing apoptosis (Caspase-3) 
and proliferation (Ki67) to evaluate if this could explain 
the in vitro proliferation and in vivo survival data. The 
number of cells expressing cleaved caspase-3 (Figure 3F) 
or Ki67 (Figure 3G) showed no change between control and 
TEM8 KO tumors, despite the differences seen in tumor 
volume and survival (Figure 3A–3D), suggesting that other 
mechanisms are responsible for these effects.
TEM8 promotes tumor angiogenesis in vivo and 
stimulates endothelial cell migration in vitro
TEM8 was originally discovered in human tumor 
endothelium [4] and has been associated with tumor 
angiogenesis [2]. Since we did not observe any differences 
in apoptosis or proliferation markers we hypothesized that 
altered angiogenesis in TEM8 KO tumors might explain 
the observed differences in tumor burden. Tumor sections 
were stained for the blood vessel marker CD31, and blood 
vessel number and area were quantified. Fewer vessels 
were observed in CD31 stainings of MDA TEM8 KO 
tumors compared to MDA control tumors (Figure 4A), 
and quantification of both vessel numbers and vessel area 
showed significantly reduced tumor angiogenesis in MDA 
TEM8 KO tumors (Figure 4A). Quantifications of CD31 
staining of SW620 control and TEM8 KO tumors also 
showed a significant reduction in vessel number and area 
(Figure 4B). 
As well as being a cell surface protein, TEM8 has 
been proposed to be secreted [29]. Thus, we investigated 
whether cancer cell-secreted TEM8 could stimulate 
endothelial cell migration and proliferation in vitro, which 
may explain the differences between the observed in vitro 
and in vivo CRC growth results. To do this, we treated 
EA.hy926 human umbilical vein cells with conditioned 
media (CM) from either control or TEM8 KO cells. In 
addition, we treated EA.hy926 cells with recombinant 
TEM8 (rTEM8) to evaluate the effect of soluble TEM8 
alone on endothelial migration. Compared to treating 
EA.hy926 cells with CM from MDA control cells, there 
was a significant decrease in endothelial cell migration 
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Figure 3: The knockout of TEM8 inhibits breast and colorectal cancer growth and prolongs survival in vivo. (A) Average 
volume of MDA orthotopic tumors over time. Statistical significance was assessed by Unpaired two-tailed t-test. The graph represents two 
independent experiments of n = 4 and n = 5 tumors per group, p = 0.0002. (B) MDA survival curves. Statistical significance was assessed 
by Log rank test, p ≤ 0.0001. (C) Average volume of SW620 subcutaneous tumors over time. Statistical significance was assessed by 
Oncotarget30179www.oncotarget.com
upon treatment with CM from MDA TEM8 KO cells 
(Figure 4C). A similar although not statistically significant 
trend was observed on endothelial cell migration upon 
treatment with CM from SW620 control or SW620 TEM8 
KO cells (Figure 4C). Furthermore, EA.hy926 cells treated 
with rTEM8 displayed significantly increased migration 
compared to EA.hy926 cells treated with serum free 
medium (SFM) (Figure 4C), demonstrating that  secreted 
TEM8 was able to stimulate migration in EA.hy926 
cells. In contrast, EA.hy926 cell proliferation was not 
altered upon CM stimulation with or without TEM8, or 
stimulation with rTEM8 (Supplementary Figure 4). 
Together with the in vivo data, these results support 
a role for tumor-derived TEM8 in promoting angiogenesis 
through increased migration, but not proliferation, of 
endothelial cells. 
The loss of TEM8 inhibits breast cancer 
metastasis 
As angiogenesis is important in the invasion-
metastasis cascade, and disseminating tumor cells typically 
escape the primary tumor via blood and lymphatic vessels 
[30], the anti-angiogenic effects of the TEM8 KO seen in 
breast and CRC tumors could have an effect on metastasis. 
We first used a Matrigel invasion assay to assess the 
importance of TEM8 for the invasive capacity of MDA cells 
and found that MDA TEM8 KO cells invaded significantly 
less compared to MDA control cells (Figure 5A). These in 
vitro results suggest that TEM8 may affect the metastatic 
burden of breast cancer in vivo.
To assess this possibility, we stained satellite, axillary 
and brachial lymph nodes collected from orthotopic breast 
tumor-bearing mice for the presence of tumor cells using a 
broad-spectrum cytokeratin (PanCK) antibody. Cytokeratin 
staining is routinely used in the clinic to detect and stage 
breast cancer metastasis [31, 32]. The cytokeratin staining 
showed a significant decrease in the number of cancer 
cells present in all lymph node types from mice with MDA 
TEM8 KO tumors compared to lymph nodes from mice 
with control tumors (Figure 5B–5C). 
These findings demonstrate that TEM8 plays a role 
in breast tumor cell invasion and metastasis. 
DISCUSSION
In this study, we show that TEM8 regulates the 
expression of multiple genes. In particular, we observed 
that the most common expression changes conserved 
between breast and colorectal cancer are involved in 
regulation of the cell cycle. In line with the microarray 
results we show that TEM8 regulates cancer cell 
proliferation and primary tumor growth. Since TEM8 KO 
tumors presented with fewer blood vessels we hypothesize 
that TEM8 contributes to the regulation of angiogenesis, 
likely by being secreted by cancer cells to alter endothelial 
cell migration and thereby supporting growth of the 
tumor (Figure 5D). Moreover, we confirm that TEM8 is 
an important player in driving tumor cell invasion and 
metastatic dissemination in breast cancer. 
To our knowledge this is the first study to utilize 
CRISPR/Cas9 to permanently disrupt the TEM8 gene in 
cancer cells to study its tumorigenic effects. Since TEM8 
has been shown to promote tumor angiogenesis [2, 4], which 
is also important for tumor growth [15], we assessed blood 
vessel number in TEM8 KO tumors. We hypothesized 
that reduced angiogenesis could explain the significantly 
slower growth of TEM8 KO tumors compared to controls, 
and found that tumor angiogenesis indeed was significantly 
reduced when TEM8 expression was disrupted. Furthermore, 
CM from TEM8 KO cells did not stimulate endothelial 
cell migration to the same extent as CM from TEM8-
expressing cells. One could speculate that reduction in tumor 
angiogenesis due to loss of TEM8 could lead to an increase 
in hypoxic areas, which in turn could initiate pro-metastatic 
programs [33]. However, our data show reduced lymph node 
metastasis (Figure 5B–5C) suggesting this is not the case here.
Cancer cells are known to secrete pro-angiogenic 
signals such as vascular endothelial growth factor A 
(VEGFA) and induce an angiogenic-switch by engaging the 
tumor microenvironment [34]. We have previously shown 
that SW620 cells express LOX which stimulates secretion 
of VEGF into the CM, thereby affecting angiogenesis [35]. 
MDA-MB-231 cells can also secrete VEGF into the CM 
[36]. Combined targeting of TEM8 and VEGFR2 was 
more efficacious compared to targeting either one alone 
[2]. This suggests that TEM8 likely functions together with 
other factors, such as VEGF, to promote endothelial cell 
migration and angiogenesis.   
Most angiogenic inhibitors that have been discovered 
to date cannot distinguish between physiological and 
cancer-related angiogenesis, and this has been a problem 
when using anti-angiogenic drugs in the clinic. As few 
physiological roles for TEM8 have been confirmed and 
TEM8 is mainly expressed by cancer cells and cancer-
associated vasculature [4, 37], TEM8 could be a promising 
target for blocking tumor angiogenesis without eliciting 
the same side-effects and toxicity as other anti-angiogenic 
Unpaired two-tailed t-test, two independent experiments of n = 6 tumors per group, p = 0.0382, (D) SW620 survival curves. Statistical 
significance was assessed by Log rank test, two independent experiments of n = 3 mice per group, p = 0.0108. (E) TEM8 expression in 
TEM8 KO and control tumors was assessed by IHC. (F) IHC of cleaved caspase 3 in TEM8 KO and control tumors (left). Quantification 
of cleaved caspase 3 expression (right). Statistical significance was assessed by Unpaired two-tailed t-test n = 4 tumors, not significant (ns). 
(G) IHC of Ki67 expression in TEM8 KO and control tumors (left). Quantification of Ki67 expression (right). Statistical significance was 
assessed by Unpaired two-tailed t-test, n = 4 tumors, ns. (A+C) Data represented as mean + SEM. (F–G) Data represented as mean ± SEM. 
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Figure 4: TEM8 promotes vessel formation in breast and colorectal tumors. (A) Left, representative micrographs and 
corresponding magnified areas showing CD31 (red) and cell nuclei (DAPI, blue) in orthotopic MDA tumors. Rigth, quantification of 
vessel number and vessel area. Statistical significance was assessed by unpaired two tailed t-test, n = 5 mice, vessel number: p = 0.0054, 
area: p = 0.0225. (B) Left, representative micrographs and corresponding magnified areas showing CD31 (red) and cell nuclei (DAPI, blue) 
in subcutaneous SW620 tumors. Right, quantification of vessel number and vessel area. Statistical significance was assessed by unpaired 
two tailed t-test, n = 5 mice, vessel number: p = 0.0222, area: p = 0.0130. (C) Percent wound closure in endothelial EA.hy926 cells after 
eleven hours of migration treated with CM from TEM8 control or TEM8 KO cells, or recombinant TEM8 (rTEM8) as indicated. Serum 
free medium (SFM) was included as a negative control. Statistical significance was assessed by unpaired two-tailed t-test between MDA 
ctrl and TEM8 KO CM (p = 0.454) and unpaired two-tailed t-test between rTEM8 and SFM treated EA.hy926 cells (TEM8, p = 0.0261), 
n = 3 independent experiments. 
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Figure 5: The knockout of TEM8 reduces lymph node metastasis. (A) Representative micrographs of MDA cell invasion 
through Matrigel coated Boyden chamber invasion inserts (left) and the corresponding invasion index (right). Statistical significance was 
assessed by unpaired two tailed t-test, n = 4 independent experiments, p = 0.0279. (B) IHC of Cytokeratin (PanCK) expression in lymph 
nodes (LN) from orthotopic MDA control and TEM8 KO tumor bearing mice. Right panels show magnified areas. (C) Quantification of 
cytokeratin expressing cells in lymph nodes. Statistical significance was assessed by unpaired two-tailed t-test between all MDA control 
lymph nodes and all MDA TEM8 KO lymph nodes (three LNs per mouse, four mice in each group), p ≤ 0.0001. (D) Suggested mechanism 
behind the impact of TEM8 on breast and CRC cancer progression. TEM8 expressed by cancer cells stimulates cancer cell proliferation. 
Cancer cell-secreted TEM8 affects endothelial cell (EC) migration and thereby increases tumor angiogenesis. This increase in tumor 
angiogenesis creates a favorable escape route for cancer cells embarking on the metastatic cascade. On the other hand, disruption of TEM8 
induces the expression of cell cycle and kinetochore-related genes, resulting in reduced cancer cell proliferation and reduced angiogenesis, 
leading to reduced primary tumor growth and metastasis. 
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cancer therapies [38–40]. In agreement with our data and 
this hypothesis, another study showed that treatment with 
a TEM8-targeting antibody inhibited tumor proliferation 
and reduced the number of tumor blood vessels, without 
targeting normal physiology in mice [2]. 
The observed reduction of tumor blood vessel 
number in TEM8 KO tumors led us to investigate whether 
TEM8 is also important for metastasis, as disseminating 
cancer cells leave the primary tumor by entering the 
blood stream through the tumor blood vessel system [8]. 
We found that the number of disseminating tumor cells 
present in the lymph nodes of breast cancer-bearing nude 
mice was dramatically reduced when TEM8 expression 
was abolished (Figure 5), confirming that TEM8 supports 
metastasis. In line with our data, knock-down of TEM8 
was previously shown to reduce lung metastasis and 
invasion of TMD-231 breast cancer cells into Matrigel 
[20], and overexpression of TEM8 in a 4T1 murine model 
of breast cancer resulted in increased colony formation 
in lymph and lung clonogenic assays [3]. Correlating 
with these results, treatment with an antibody-like TEM8 
targeting molecule was found to inhibit liver metastasis of 
MCF-7 xenografts in mice [41], indicating that targeting 
TEM8 could be an anti-metastasis therapeutic approach 
in breast cancer. It has not yet been established where in 
the metastatic cascade TEM8 plays a role, and in order to 
investigate TEM8’s role in metastasis further, it would be 
interesting to assess the different metastatic steps; invasion 
(tumor cells escaping the primary tumor), circulation in 
the bloodstream, extravasation at secondary sites and 
initiation of angiogenesis at secondary sites [8]. Our in 
vitro and angiogenesis data show that breast tumor cell 
invasion was reduced in TEM8 KO cells, suggesting that 
TEM8 could be important in the first step of the metastatic 
cascade: escaping from the primary tumor (Figure 5D). 
Our microarray data showed that the expression of 
genes regulating the cell cycle was up-regulated in TEM8 KO 
cancer cells. Up-regulation of this gene cluster could explain 
the reduced cell division and thus reduced proliferation and 
tumor growth of TEM8 KO cells compared to control cells. 
In support of our results, the loss of TEM8 has previously 
been linked to reduced proliferation by increasing p21 
and p27 levels and by suppressing levels of cyclin D1 in 
osteosarcoma cell lines [20]. Similarly, cell cycle-related 
pathways were altered in a  microarray analysis of breast 
cancer TMD-231 TEM8 shRNA cells [20].
 Furthermore, a cluster of genes involved in 
kinetochore was up-regulated in both TEM8 KO cell lines, 
suggestive of a change in cell division and protein levels 
in the cancer cells. A network analysis showed that the KO 
of TEM8 changed the expression of several genes in close 
network proximity with TEM8 (Supplementary Figure 2), 
indicating that TEM8 plays a regulatory role driving 
cancer progression in both breast and colorectal cancer.
In summary, we found TEM8 to be upregulated in 
the normal-like cell states of tumors, and to be significantly 
higher in tumors than in cell states of normal breast and 
colorectal tissue. Experiments performed using CRISPR/
Cas9 engineered TEM8 KO metastatic breast and colorectal 
cancer cell lines highlights a role for TEM8 in cancer 
progression, tumor angiogenesis and local metastasis. 
We propose that TEM8 targeting may provide a viable 
therapeutic treatment strategy against breast cancer and 
CRC tumor burden and metastasis. TEM8 was originally 
thought not to be expressed in normal tissue [4, 10], 
although it has since been shown by PCR to be broadly 
expressed, five splice variants of TEM8 have been detected 
[29], and studies in the most recent TEM8 KO mouse 
show a role for TEM8 during development [16]. However, 
we verified that TEM8 is up-regulated in cancer tissue 
compared to healthy, and treatment with a TEM8 antibody 
was reported to result in inhibited angiogenesis, reduced 
tumor growth and increased survival with no toxicity effects 
in a cancer setting [2]. TEM8 targeting could therefore be 
an alternative approach to more specifically block tumor 
angiogenesis compared to current clinically approved anti-
angiogenic therapies. Further clinical studies are needed to 
explore the full potential of TEM8-targeted therapy. 
MATERIALS AND METHODS
Disease-specific genomic analysis
Disease-Specific Genomic Analysis (DSGA) [22], 
is a computational data analysis method that provides a 
decomposition of log-transformed tumor data T into a 
normal component (NcT) and a disease component (DcT). 
The normal component NcT is the best approximation 
of the tumor signature by a “normal-like” cell state. 
The disease component DcT is the deviation from this 
normal-like state, thereby highlighting the “aberrant” cell 
state. T = NcT + DcT. For breast cancer analysis gene 
expression microarray data from a breast cancer cohort 
at the Dutch Cancer Institute (NKI) (n = 295) [23] and 
normal samples (normal breast tissue (BCN) [22] (n = 13), 
pathologically normal breast distant to tumors in breast 
cancer patients (n = 10), and reduction mammoplasties 
(n = 3)) were used. Luminal tumors were not separated 
into molecular types (Luminal A and Luminal B). The 
separation of tumors into basal-like, her2-overexpressing 
and Luminal was based on ESR1 and ERBB2 status in the 
disease component, both of which have a clear bimodal 
distribution, allowing assignment of status based on DcT 
component of gene expression. Of the 295 tumors, 53 were 
her2-overexpressing by DcT analysis. One was borderline, 
ERBB2 overexpressing and thus was not included in the 
survival analysis. The same was observed when tumors 
were not separated by ESR1 and her2 status. 
For analysis of TEM8 expression in CRC the 
published GSE77953 affymetrix HG-U133A data set 
[24] and ANTXR1 probe 220092_s_at were used. The 
CRC data set consisted of normal tissue samples (normal 
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colonic crypts (n = 7) and normal colonic surface 
epithelium (n = 6)) and CRC samples (adenomas (n = 17), 
carcinomas (n = 17) and metastases (n = 11)).
All analyses and plots were performed using R 
version 3.4.4 with standard Bioconductor version 3.6 and 
the following packages: DSGA [22], survival, RMA, and 
ggpubr.
Cell lines
The metastatic breast cancer cell line MDA-
MB-231 (MDA) was derived from a patient with breast 
adenocarcinoma [42], the human metastatic CRC cell line 
SW620 was derived from a lymph node metastasis from 
a patient with colon adenocarcinoma [43], the HEK-293 
cell line was derived from human embryonic kidney cells 
[44], and the EA.hy926 cell line was derived from human 
umbilical vein cells [45]. All cell lines were maintained at 
37° C and 5% CO2 in Dulbecco’s modified Eagle medium 
(1x) GlutaMAX (DMEM, Gibco, ThermoFisher Scientific, 
Waltham, MA, USA) containing 10% Fetal Bovine Serum 
(FBS; Gibco) and 1% Penicillin Streptavidin (Gibco). All 
cell lines were validated by short tandem repeat (STR) 
analysis and routinely tested for mycoplasma. 
CRISPR/Cas9 mediated generation of TEM8 
KO cells 
MDA and SW620 TEM8 KO cells were generated 
using the plasmids pSPCas9 (BB)-2A-Puro (PX459) 
V2.0 (Addgene plasmid #62988) and pSpCas9n(BB)-
2A-GFP (PX461) V2-0 (Addgene plasmid #48140), both 
a gift from Feng Zhang, according to published protocols 
[46, 47]. gRNAs targeting the first exon of TEM8 were 
designed using http://crispr.mit.edu. gRNAs were cloned 
into PX459 and PX461 CRISPR/Cas9 plasmids and cells 
were transfected using Lipofectamine 2000 as described 
previously [46]. To create MDA TEM8 KO the following 
gRNAs and plasmid were used: TEM8 KO gRNA1 
Forward (5ʹ-CACCGCAGGTCAAATCCGCCGTAGC-
3ʹ)/ TEM8 KO gRNA1 Reverse (5ʹ-AAACGCTACGG 
CGGATTTGACCTGC-3ʹ) and PX459. To create SW620 
TEM8 KO the following gRNAs and plasmid were used: 
TEM8 KO gRNA2 Forward (5ʹ-CACCGTGCTCATCT 
GCGCCGGGCAA-3ʹ)/ TEM8 KO gRNA2 Reverse 
(5ʹ-AAACTTGCCCGGCGCAGATGAGCAC-3ʹ), TEM8 
KO gRNA3 Forward (5ʹ-CACCGCCACTGGAAGCCGA 
TGCCG-3ʹ)/TEM8 KO gRNA3 Reverse (5ʹ-AAACC 
GGCATCGGCTTCCAGTGGC-3ʹ) and PX461. Success-
fully transfected cells were either selected using 4 µg/ml 
puromycin or FACS sorted for GFP expression as 
appropriate. Selected TEM8 KO cell lines were verified 
by Sanger sequencing, The primer pair TEM8 forward 
(5ʹ-GCGAGGGGGAATAAAGGACC-3ʹ)/ TEM8 reverse 
(5ʹ-TAATGCCTTCCGTGGGACAG-3ʹ) was used for 
sequencing. TEM8 gDNA was amplified by polymerase 
chain reaction (PCR) using the Phusion Flash High-
Fidelity PCR Master Mix (ThermoFisher Scientific). 
PCR amplicons were purified using GFX PCR DNA and 
Gel band Purification Kit (GE Healthcare Life Science, 
Cleveland, OH, USA) according to manufacturer’s 
instructions. The PCR amplicons were sequenced at GATC-
Biotech (Constance, Germany) and ABI sequencing files 
were analyzed by Geneious [48] and by CRISPR ID [49].
RNA and DNA extraction 
Two hundred and fifty thousand MDA or 6.25 × 105 
SW620 cells were seeded in a 6-well plate format. The 
cells were incubated at 37° C overnight. RNA or genomic 
DNA was collected according to the manufacturer’s 
instructions using an RNeasy kit (Qiagen, Venlo, 
Netherlands) or collected using a genomic DNA (gDNA) 
kit (Qiagen), respectively. 
RT-qPCR
Primers targeting the TEM8 DNA sequence 
downstream of the TEM8 DNA indels were designed in 
order to detect changes in mRNA expression levels caused 
by TEM8-targeting CRISPR/Cas9: TEM8 forward (5ʹ-TGG 
GTCCTACTGAGGAAAGG-3ʹ)/ TEM8 reverse (5ʹ-GACC 
CTGGTGAAGTTGATGC-3ʹ) and β-tubulin forward 
(5ʹ-GCGAGATGTACGAAGACGAC-3ʹ)/β-tubulin reverse 
(5ʹ-TTTAGACACTGCTGGCTTCG-3ʹ). 2 µg RNA from 
the CRISPR modified cancer cells was reverse translated 
into complementary DNA (cDNA) with Moloney Leukemia 
Virus Reverse Transcriptase (ThermoFisher Scientific). 
10 µl LightCycler 480 SYBR Green Master (Roche, Basel, 
Switzerland) pr. 50–100 µg cDNA and 0.5 µM primers was 
used as detection method. Samples were run in a Lightcycler 
480 II (Roche). Tubulin was used as an internal 
expression control. Samples were run in triplicate. 
Gene expression microarray
A One-Color SurePrint G3 Human Gene Expression 
version 3 microarray (Agilent, Santa Clara, CA, USA), 
comparing gene expression in MDA-MB-231 and SW620 
TEM8 KO cell lines to their respective control cell lines, 
was carried out according to manufacturer’s instructions 
(n = 3). The comparison of log fold differences in gene 
expression between TEM8 KO and control cell lines were 
found by using the average value for probes corresponding 
to one gene. The pair-wise comparison was performed on 
the average values of the three individual repeats.  
Bioinformatics analyses of microarray data
Gene expression values from both MDA and SW620 
cell lines were hierarchically clustered on the basis of 
uncentred Pearson correlation using Cluster 3.0 [50] (C 
Clustering Library, version 1.52) and visualized using 
Java TreeView [51] (version 1.1.6r4). Fifteen clusters were 
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chosen on the basis of a Pearson correlation threshold 
greater than 0.8 (Figure 2C). Functional enrichment 
analysis of clustered genes was performed using DAVID 
[52] (version 6.7) using biological process and cellular 
component gene ontology categories. Keywords with fold 
enrichment ≥1.5, Bonferroni-corrected P value < 0.05, 
EASE score (modified Fisher’s exact test) < 0.05 and at least 
two genes per keyword were considered significantly over-
represented. Interaction network analysis was performed 
using Cytoscape [53] (version 3.0.2). Gene names were 
mapped onto a merged human interactome consisting 
of protein–protein interactions reported in the Protein 
Interaction Network Analysis database [54], the MatrixDB 
database [55] and the literature-curated integrin adhesome 
[56, 57]. TEM8, the TEM8-binding proteins BRCA1, 
HDAC2 and LRP6; and their associated interacting proteins 
were extracted and displayed as networks. Node color 
represents expression changes between control and TEM8 
KO cells in MDA (Supplementary Figure 2A) and SW620 
(Supplementary Figure 2B) cell lines. 
In vivo studies 
Female CD1 homozygous nude mice (Scanbur, 
Karlslunde, Denmark) were used for all in vivo experiments. 
Mice were received at an age of 6–8 weeks and kept for 
1 week before starting experiments. All experiments were 
carried out under authorization and guidance according to 
the Danish Inspectorate for Animal Experimentation.
Mammary fat pad tumors 
Ten million MDA control or TEM8 KO cells in 
100 μl PBS were injected into the inguinal 4th right 
mammary fat pad of 8–10 week old female nude mice 
(two individual repeats of five mice per cell line). 1 ml 
syringes and 25 gauge needles (BD Biosciences) were used 
for the injections. Tumor volume and body weight were 
measured twice weekly using a digital caliper (Faithfull 
tools, Norwich, UK). Mice were sacrificed using cervical 
dislocation when tumors reached a size of 1000 mm3. 
Tumors were collected and a part of each tumor was snap 
frozen in dry ice and kept for protein, DNA and RNA 
analyses and immunofluorescence (IF). A second part of 
the tumor and lymph nodes (satellite, axillary and brachial) 
were embedded in paraffin after 24 h in formalin (Sigma 
Aldrich) and stored for immunohistochemistry (IHC). 
Subcutaneous CRC tumors 
SW620 control or TEM8 KO cells were implanted 
as subcutaneous tumors in 8–10 week old female nude 
mice (two repeats of six tumors, 3 mice per cell line) as 
previously described [58]. Tumor volume and body weight 
were measured twice weekly using a caliper. Mice were 
sacrificed and tumors collected and processed as described 
above. 
Immunohistochemistry 
Formalin-fixed, paraffin-embedded tumors were 
cut into 3 μm sections on a Microm HM355S microtome 
(Thermo Scientific) and placed on Superfrost slides. 
Sections were deparaffinized in xylene, hydrated in 
ethanol and rinsed in tap water. Antigens were retrieved 
with TEG Buffer (10 mM Tris, 0.5 mM EGTA, pH 9.0 in 
ultra pure water) at 98° C for 15 min (Ki67 and Caspase 3) 
or with Proteinase K Buffer (50 mM Tris, 0,5 M EDTA, 
pH 8,0, 0.5 ug/ml Proteinase K) at 37° C for 15 min 
(PanCytokeratin). For TEM8 IHC no antigen retrieval 
was performed. Endogen peroxidases was blocked with 
1% H2O2 (VWR International, Søborg, Denmark) in MQ 
for 15 min. Slides were rinsed in TBS with 0.5% Triton-X 
100 (TBS-Tx) and incubated in 100 μl Antibody Diluent 
with background reducing agents (DAKO, Copenhagen, 
DK) and primary antibodies (rabbit anti-human TEM8 
(ab21270, Abcam) at 1:300 dilution, rabbit anti-human 
cleaved caspase 3 (D175, Cell Signaling Technology) at 
1:500 dilution, rabbit anti-human Ki67 (ab92742, Abcam) 
at 1:1000 dilution, hamster anti-human CD31/ PECAM-1 
(MA3105, Thermo Fisher) at 1:100 dilution, rabbit anti-
human PanCytokeratin (PanCK) (ab9377, Abcam) at 1:100 
dilution) as appropriate at 4° C overnight. Slides were rinsed 
in TBS-Tx and incubated in 100 μl EnVision+ System–HRP 
secondary antibody (DAKO) corresponding to the host 
of the primary antibody for 45 min. Subsequently slides 
were rinsed in TBS-Tx and incubated in 150 μl NovaRED 
(Vector laboratories, Burlingame, CA, USA) for 10 min 
to visualize antibody-positive cells followed by rinsing in 
MQ water and incubation in 100 μl Meyers Hematoxyline 
(Sigma Aldrich) for exactly 30 sec to visualize cell nuclei. 
Slides were rinsed in tap water, dehydrated in ethanol and 
mounted on coverslips with DPX mount for histology 
(Sigma Aldrich). Slides were scanned with a NanoZoomer 
digital slide scanner (Hamamatsu, Bridgewater, NJ, USA) 
and the number of protein-expressing cells in each tumor 
was quantified manually with the NDP view 2 software 
(Hamamatsu). 
Immunofluorescence
Snap frozen tumors were cut into 5 μm sections and 
placed on Superfrost slides. Sections were fixed in 4% PFA 
for 10 min, rinsed in TBS with 0.05% Tween (TBST) and 
permeabilized using 1% TBS-Tx for 30 min. Unspecific 
protein binding was blocked with 5% normal serum from 
the host of the secondary antibody diluted in TBST for 30 
min.  Slides were incubated in primary antibody diluted in 
TBST at 4° C overnight. Slides were then rinsed in TBST 
and incubated with secondary antibody diluted in TBST 
for 1 h. Finally, slides were incubated with Dapi 1:1000 
(ThermoFisher Scientific) for 10 min to visualize nuclei, 
and mounted using glass coverslips. Tumor sections were 
visualized on a DeltaVision (GE Healthcare Lifescience), 
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and Velocity software (PerkinElmer, Waltham, MA, USA) 
was employed to evaluate protein expression levels.
Conditioned media 
Conditioned media (CM) was collected from cells 
as previously described [35]. Briefly, cells where seeded 
in complete media, after 24 h cells were washed twice 
with PBS and serum free media was added. After 24 h 
conditioned media (CM) was harvested. CM was added to 
complete media at a ratio of 1:20 and added to EA.hy926 
cells. Complete media with 10 ng/ml recombinant TEM8 
(Novus Biologicals, Littleton, CO, USA) or serum 
free medium (SFM) as negative control were added as 
appropriate.
Scratch wound assay
One hundred and seventy five thousand EA.hy926 
cells were seeded in a 12-well plate format in complete 
medium and incubated for 16 h. Cells were serum deprived 
in medium with 3% FBS for 3 h. Scratches were made in 
the EA.hy926 cell layer using a sterile pipette tip, and wells 
were subsequently rinsed in medium with 3% FBS. Wells 
were supplemented with 3% FBS medium with CM in 
duplicate and incubated in an IncuCyte at 37° C. Percentage 
wound closure was calculated using ImageJ software. 
Boyden chamber cell invasion assay
Twenty four-well format migration or invasion inserts 
with a pore size of 8.0 µm with no coating or Matrigel 
coating, respectively (Corning, NY, USA) were used for 
this assay. Cells were serum starved overnight. Inserts were 
rehydrated in 500 μl serum free medium for 2 h. 2.5 × 104 
cells in 400 μl serum free medium were added to the inner 
wells in duplicate. 600 μl complete medium was added to 
the outer well to promote migration or invasion. Inserts 
were then incubated at 37° C. After 24 h, the medium was 
aspirated and non-migrating cells were removed from inner 
wells using cotton buds before fixing cells by adding 750 μl 
methanol for 15 min, followed by 600 μl 0.1% Crystal 
Violet for 20 min at room temperature for visualization. 
Invading or migrating cells were imaged and counted on 
an Olympus BX51 microscope (Olympus, Tokyo, Japan) 
with a UIS2 4×/0.10 Plan C N ∞/-/FN22 objective. An 
invasion index was used to separate the cells invading from 
chemotactic (migrating) cells25: Invasion index = (invading 
cells/migrating cells) * 100. 
Statistics
For multiple comparisons of DSGA data one-sided 
Wilcoxon rank sum test was used for normal components, 
and two-sided Wilcoxon rank sum test was used for disease 
components. Kaplan–Meyer survival curves were used 
to compare the top and bottom thirds of TEM8 aberrant 
expression in patients with her2-overexpressing tumors. 
P-values were obtained using log-rank test. Experiments 
with two groups were analyzed with unpaired two-sided 
Student’s t-test and studies with three or more groups were 
analyzed with one-way ANOVA followed by Dunnett’s 
multiple comparison tests. Error bars represents standard 
error of the mean. Differences were considered significant 
at p < 0.05. Asterisks indicate significant differences and 
refer to the following p-values: * = p < 0.05, ** = p < 0.01, 
*** = p < 0.001, **** = p < 0.0001, ns = non-significant. 
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